Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING LLC
Ampronix

NMR-Based Diabetes Risk Index Helps to Identify Normal-Weight Individuals at High Risk of Progressing to Type 2 Diabetes

By Medimaging International staff writers
Posted on 09 Jul 2014
A nuclear magnetic resonance (NMR)-based diabetes risk index (DRI) is being used to identify normal-weight individuals at high risk of progressing to type 2 diabetes, and may enable a more comprehensive risk assessment and intervention in at-risk patients.

LipoScience, Inc. (Raleigh NC, USA), a diagnostic company that develops personalized NMR diagnostics to further the quality of patient care in cardiovascular, metabolic, and other diseases, presented data demonstrating the utility of the company’s technology on June 14, 2014, at the 74th Scientific Sessions of the American Diabetes Association (ADA), held in San Francisco (CA, USA), and suggests that the DRI may enable more timely and focused risk assessment and intervention in at-risk individuals regardless of body weight, potentially preventing or slowing their progression to type 2 diabetes.

“Many clinicians are challenged about how to effectively manage patients with ‘intermediate’ blood glucose levels ranging from 90 to 110 mg/dL, as within this range there is often ambiguity as to whether a patient will progress to type 2 diabetes,” commented Margery Connelly, PhD, vice president, translational research of LipoScience. “The ambiguity is particularly pronounced in normal-weight individuals, who do not typically present with overtly visible risk factors. With our simple-to-use diabetes risk index, clinicians now have a tool to help them identify high-risk patients, providing guidance for implementing targeted risk-reduction strategies.”

The DRI is a clinical lab test that uses LipoScience’s proprietary NMR-derived markers of insulin resistance, inflammation, and potentially impaired B-cell function to determine a patient's risk of progressing to type 2 diabetes. DRI provides researchers and healthcare providers with the means to assess a patient’s risk of progressing to diabetes at any given level of fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), or body mass index (BMI).

The investigators used NMR data gathered at baseline from participants in the Multi-Ethnic Study of Atherosclerosis (MESA), to develop the DRI assay, and then used data from and the Insulin Resistance Atherosclerosis Study (IRAS) to verify its ability to stratify a patient’s risk of progressing to type 2 diabetes. To determine whether the DRI score was capable of identifying normal-weight individuals with a high likelihood of developing diabetes, the investigators compared the percentage of patients progressing to type 2 diabetes across quartiles of the DRI score in three BMI categories—normal weight (BMI < 25), overweight (BMI 25–30), and obese (BMI ≥ 30). Regardless of the BMI category, as the DRI score increased there was an increased likelihood of becoming diabetic, even for patients whose BMI was within the normal range. Furthermore, DRI added predictive value independently of BMI in both the MESA and IRAS populations.

"Even in the absence of being overweight, DRI can help healthcare providers make a more timely prediction of whether a patient is on the path toward developing diabetes, before blood glucose reaches so-called ‘pre-diabetes’ levels,” noted William C. Cromwell, MD, chief medical officer of LipoScience. “By providing more precise risk-assessment information, DRI can facilitate initiation of individualized patient management strategies, while motivating high-risk patients to take steps to lower their risk.”

LipoScience is focused on the new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile test, the company’s first proprietary test, is the only US Food and Drug Administration (FDA)-cleared blood test that directly quantifies low-density lipoprotein (LDL) particles and provides physicians and their patients with actionable information to personalize management of heart disease.

The Vantera clinical analyzer is the first FDA-cleared platform that utilizes NMR technology. Its ease of use and quick turnaround time helps maximize efficiency and throughput in the clinical laboratory.

Related Links:

LipoScience



Channels

Radiography

view channel
Image: Bayalpata Hospital in Rural Nepal (Photo courtesy of Nyaya Health Blog).

Base of the Pyramid Digital Imaging System Built for Novel Telemedicine Applications

The remote Bayalpata Hospital in the mountains of Western Nepal has set up a system that will allow their physicians to digitize and send X-ray images to physicians in Grande hospital in Kathmandu for... Read more

MRI

view channel

Imaging Test Designed for Autism Spectrum Disorder

Scientists have developed a brain-imaging technique that may be able to identify children with autism spectrum disorder in just two minutes. Typically, diagnosis—an unquantifiable process based on clinical judgment—is time-consuming and tiresome on children and their families. That may change with this new diagnostic test.... Read more

Ultrasound

view channel

Guidelines Released for Quantitative Monitoring of Critically Ill and Surgery Patients Using Echocardiography

The American Society of Echocardiography (ASE; Morrisville, NC, USA) has published clinical guidelines describing how and when echocardiography can be used for medical and surgical therapy in adult patients. The guidelines were published in the January 2015 issue of the American Society of Echocardiography.... Read more

General/Advanced Imaging

view channel
Image: Dr. Miles was part of the team that helped identify facial measurements in children with autism that may lead to a screening tool for young children and provide clues to its genetic causes (Photo courtesy of Rebecca F. Miller).

Advanced 3D Facial Imaging Designed to Help in Early Identification of Autism

Autism is a range of closely related disorders observed in patients who exhibit a shared assortment of symptoms, including delays in learning to communicate and interrelate socially. Early detection of... Read more

Imaging IT

view channel

Findings Reveal Health Information Exchange Decreases Repeat Imaging

The use of health information exchange (HIE) systems to share reports on imaging tests, such as X-rays and magnetic resonance imaging (MRI) scans, can help reduce the number of times patients undergo the precisely same test. A new study suggests that HIE technology that gives healthcare providers immediate, electronic access... Read more

Industry News

view channel

Expected Revenues of Hologic Up in First Quarter of 2015

Hologic (Bedford, MA, USA), a global healthcare and diagnostics company, has announced that it expects total revenues for first fiscal quarter of 2015 to reach approximately USD 653 million—7% more than the year before. The company provided the business updates in preparation for its participation in the 33rd Annual J.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.